IRVING, Texas — Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the development and peer-reviewed validation of a new predictive signature to inform therapy selection in glioblastoma (GBM) patients. The study, published in Neuro-Oncology Advances, describes the development and evaluation of the model in a...
Latest News
IRVING, Texas — Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the launch of a groundbreaking AI-driven molecular insight for a subset of mono-immunotherapy eligible non-small cell lung cancer (NSCLC) patients. The NSCLC immunotherapy (IO) treatment selection signature was developed to...
SHANGHAI, China — CARsgen Therapeutics Holdings Ltd, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that CT011, an autologous CAR T-cell product candidate against Glypican-3 (GPC3), has achieved Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA)...
After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point...
Paris, France – CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces preclinical results in the testing of the combination of SonoCloud® technology with immunotherapies. This laboratory work was done in collaboration with Dr Amy Heimberger – a renowned expert in...
Shijiazhuang, China – A teenage girl was diagnosed with concomitant Wilson disease (WD) and systemic lupus erythematosus (SLE), according to a case report published in Frontiers in Pediatrics. The 17-year-old patient was initially diagnosed with SLE following positive tests for lupus anticoagulant and antinuclear antibodies, along with pleural effusion, hypocomplementemia,...
The use of tyrosine kinase inhibitor (TKI) therapy may provide a degree of protection against COVID-19 in patients with chronic myeloid leukemia (CML). These findings are suggested by in a case report and literature review published in the European Journal of Case Reports in Internal Medicine. The case report involved a...
CLEVELAND, Ohio – Oral cancers and precancerous mouth lesions are considered especially difficult to diagnose early and accurately. For one, biopsies are expensive, invasive, stressful for the patient and can lead to complications. They’re also not feasible if repeated screenings of the same lesion are required. But a team of...
São Paulo, Brazil – Analysis of occurrence and co-occurrence patterns shows the highest-risk clusters of chikungunya and zika in Brazil spreading from the Northeast to the Center-West and coastal areas of São Paulo state and Rio de Janeiro state in the Southeast between 2018 and 2021, and increasing again in...
ROCKVILLE, Md. and BEIJING – CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose escalation and expansion study of CID-103, an investigational novel anti-CD38 monoclonal antibody, in patients with previously treated, relapsed or refractory...